Clinical potential of electroporation for gene therapy and DNA vaccine delivery

Expert Opinion on Drug Delivery

Volumn 13, Issue 2, 2016, Pages 295-310

  Lambricht, Laure ^a   Lopes, Alessandra ^a   Kos, Spela ^b   Sersa, Gregor ^b   Préat, Véronique ^a   Vandermeulen, Gaëlle ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Clinical trials; DNA vaccines; electroporation; gene delivery; gene electrotransfer; gene therapy; genetic adjuvants

Indexed keywords

DNA VACCINE; INTERLEUKIN 12; INTERLEUKIN 2;

CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER THERAPY; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTRODE; ELECTROPORATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION PREVENTION; NEOPLASM; NERVE STIMULATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMID; PROTEIN EXPRESSION; PULSE RATE; REVIEW; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; IMMUNOLOGY; PROCEDURES;

DRUG DELIVERY SYSTEMS; ELECTROPORATION; GENETIC THERAPY; HUMANS; PLASMIDS; VACCINES, DNA;

EID: 84957430721     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1121990     Document Type: Review

References (83)

1. Kaestner L, Scholz A, Lipp P. Conceptual and technical aspects of transfection and gene delivery. Bioorg Med Chem Lett. 2015;25(6):1171-1176.
2. Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39(1):4-16.
3. Yarmush ML, Golberg A, Sersa G, et al. Electroporationbased technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng. 2014;16:295-320.
4. Denet AR, Vanbever R, Preat V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev. 2004;56(5):659-674.
5. Bennett WF, Sapay N, Tieleman DP. Atomistic simulations of pore formation and closure in lipid bilayers. Biophys J. 2014;106(1):210-219.
6. Rols MP. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim Biophys Acta. 2006;1758(3):423-428.
7. Teissie J, Golzio M, Rols MP. Mechanisms of cell membrane electropermeabilization: a minireview of our present (lack of ?) knowledge. Biochim Biophys Acta. 2005;1724(3):270-280.
8. Gothelf A, Gehl J. What you always needed to know about electroporation based DNA vaccines. Hum Vacc Immunother. 2012;8(11):1694-1702.
9. Marszalek P, Liu DS, Tsong TY. Schwan equation and transmembrane potential induced by alternating electric field. Biophys J. 1990;58(4):1053-1058.
10. Kotnik T, Pucihar G, Miklavcic D. Induced transmembrane voltage and its correlation with electroporation-mediated molecular transport. J Membr Biol. 2010;236(1):3-13.
11. Kotnik T, Pucihar G. Induced transmembrane voltage - theory, modeling, and experiments. In: Pakhomov AG, Miklavcic D, Markov MS, editors. Advanced electroporation techniques in biology and medicine. Boca Raton (FL): CRC Press; 2010.
12. Kotnik T, Frey W, Sack M, et al. Electroporation-based applications in biotechnology. Trends Biotechnol. 2015;33 (8):480-488.
13. Miklavcic D, Beravs K, Semrov D, et al. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J. 1998;74(5):2152-2158.
14. Hirao LA, Wu L, Khan AS, et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine. 2008;26(3):440-448.
15. Wells DJ. Gene therapy progress and prospects: Electroporation and other physical methods. Gene Ther. 2004;11(18):1363-1369.
16. Bolhassani A, Khavari A. Orafa Z electroporation - advantages and drawbacks for delivery of drug, gene and vaccine. In: Sezer AD, editor. Nanotechnology in drug delivery. Rijeka: InTech; 2014.
17. Gehl J. Gene electrotransfer in clinical trials. Methods Mol Biol. 2014;1121:241-246.
18. Heller LC, Heller R. In vivo electroporation for gene therapy. Human Gene Therapy. 2006;17(9):890-897.
19. Senovilla L, Vacchelli E, Garcia P, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2013;2(4): e23803.
20. Kobiyama K, Jounai N, Aoshi T, et al. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines. 2013;1(3):278.
21. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol. 2004;110(1):1-10.
22. Chiarella P, Massi E, De Robertis M, et al. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther. 2008;8(11):1645-1657.
23. Weaver JC. Electroporation theory Concepts and mechanisms. Methods Mol Biol. 1995;55:3-28.
24. Andreason G. Electroporation as a technique for the transfer of macromolecules into mammalian cell lines. J Tissue Culture Methods. 1993;15(2):56-62.
25. Staal L, Gilbert R. Generators and applicators: equipment for electroporation. In: Kee ST, Gehl J, Lee EW, editors. Clinical aspects of electroporation. New York (NY): Springer; 2011. p. 45-65.
26. Heller R, Heller LC. Gene electrotransfer clinical trials. Adv Genet. 2015;89:235-262.
27. El-Kamary SS, Billington M, Deitz S, et al. Safety and Tolerability of the Easy Vax Clinical Epidermal Electroporation System in Healthy Adults. Mol Ther. 2012;20(1):214-220.
28. Spanggaard I, Snoj M, Cavalcanti A, et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev. 2013;24(3):99-107.
29. Eriksson F, Tötterman T, Maltais A-K, et al. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine. 2013;31(37):3843-3848.
30. Wallace M, Evans B, Woods S, et al. Tolerability of Two Sequential Electroporation Treatments Using MedPulser DNA Delivery System (DDS) in Healthy Adults. Mol Ther J Am Soc Gene Ther. 2009;17(5):922-928.
31. Diehl MC, Lee JC, Daniels SE, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vacc Immunother. 2013;9 (10):2246-2252.
32. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6(5): e19252.
33. Yuan J, Ku GY, Adamow M, et al. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer. 2013;1:20-20.
34. Kim TJ, Jin H-T, Hur S-Y, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.
35. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis. 2013;208(5):818-829.
36. Mpendo J, Mutua G, Nyombayire J, et al. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIVSeronegative African Adults. PLoS One. 2015;10(8): e0134287.
37. Weiland O, Ahlen G, Diepolder H, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther. 2013;21(9):1796-1805.
38. Hooper JW, Moon JE, Paolino KM, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clin Microbiol Infect. 2014;20(Suppl 5):110-117.
39. Yang B, Jeang J, Yang A, et al. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10 (11):3153-3164.
40. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4 (155):155ra38.
41. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078-2088.
42. Lucas ML, Heller L, Coppola D, et al. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5(6):668-675.
43. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5896-5903.
44. Welch M, Villalobos A, Gustafsson C, et al. You're one in a googol: optimizing genes for protein expression. J Royal Soc Interface. 2009;6(Suppl 4):S467-S76.
45. Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet. 2011;12(1):32-42.
46. Angov E. Codon usage: Nature's roadmap to expression and folding of proteins. Biotechnol J. 2011;6(6):650-659.
47. Kotsopoulou E, Kim VN, Kingsman AJ, et al. A Rev- Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1 gag-pol Gene. J Virol. 2000;74(10):4839-4852.
48. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol. 2012;162(2-3):171-182.
49. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189-209.
50. Papadakis ED, Nicklin SA, Baker AH, et al. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 2004;4(1):89-113.
51. Vandermeulen G, Richiardi H, Escriou V, et al. Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine. 2009;27(32):4272-4277.
52. Danda R, Krishnan G, Ganapathy K, et al. Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy. Plos One. 2013;8(12):e83398.
53. Kos S, Tesic N, Kamensek U, et al. Improved specificity of gene electrotransfer to skin using pDNA under the control of collagen tissue-specific promoter. J Membr Biol. 2015;248(5):919-928.
54. Bode C, Zhao G, Steinhagen F, et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499-511.
55. Tudor D, Dubuquoy C, Gaboriau V, et al. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine. 2005;23(10):1258-1264.
56. Babiuk S, Mookherjee N, Pontarollo R, et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology. 2004;113(1):114-120.
57. Vandermeulen G, Marie C, Scherman D, et al. New Generation of Plasmid Backbones Devoid of Antibiotic Resistance Marker for Gene Therapy Trials. Mol Ther. 2011;19(11):1942-1949.
58. Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines. 2014;2(1):89.
59. Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccineplatforms for the battle against infectious diseases. Clin Exp Vaccine Res. 2015;4(1):1-10.
60. Weiss JM, Subleski JJ, Wigginton JM, et al. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther. 2007;7(11):1705-1721.
61. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118 (2):503-508.
62. Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013;4:354.
63. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine. 2001;19(17-19):2647-2656.
64. Sersa G, Teissie J, Cemazar M, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother. 2015;64 (10):1315-1327.
65. Vandermeulen G, Vanvarenberg K, De Beuckelaer A, et al. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation. Vaccine. 2015;33(28):3179-3185.
66. Gothelf A, Gehl J. Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther. 2010;10(4):287-299.
67. Gothelf A, Mahmood F, Dagnaes-Hansen F, et al. Efficacy of transgene expression in porcine skin as a function of electrode choice. Bioelectrochemistry. 2011;82(2):95-102.
68. Maruyama H, Ataka K, Higuchi N, et al. Skin-targeted gene transfer using in vivo electroporation. Gene Ther. 2001;8(23):1808-1812.
69. Daugimont L, Baron N, Vandermeulen G, et al. Hollow Microneedle Arrays for Intradermal Drug Delivery and DNA Electroporation. J Membrane Biol. 2010;236(1):117-125.
70. Sersa G, Miklavcic D, Cemazar M, et al. Electrochemotherapy in treatment of tumours. Ejso-Eur J Surg Onc. 2008;34(2):232-240.
71. Heller R, Cruz Y, Heller LC, et al. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Human Gene Therapy. 2010;21(3):357-362.
72. Guo SQ, Donate A, Basu G, et al. Electro-gene transfer to skin using a noninvasive multielectrode array. J Control Release. 2011;151(3):256-262.
73. Drabick JJ, Glasspool-Malone J, Somiari S, et al. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther. 2001;3(2):249-255.
74. Donate A, Coppola D, Cruz Y, et al. Evaluation of a Novel Non-Penetrating Electrode for Use in DNA Vaccination. Plos One. 2011;6:4.
75. Pavselj N, Preat V. DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Control Release. 2005;106(3):407-415.
76. Roos AK, Eriksson F, Walters DC, et al. Optimization of Skin Electroporation in Mice to Increase Tolerability of DNA Vaccine Delivery to Patients. Mol Ther. 2009;17 (9):1637-1642.
77. Andre FM, Gehl J, Sersa G, et al. Efficiency of High- and Low-Voltage Pulse Combinations for Gene Electrotransfer in Muscle, Liver, Tumor, and Skin. Human Gene Therapy. 2008;19(11):1261-1271.
78. Rabussay D, Dev NB, Fewell J, et al. Enhancement of therapeutic drug and DNA delivery into cells by electroporation. J Phys D Appl Phys. 2003;36(4):348-363.
79. Rabussay D, Widera G, Zhang L, et al. Toward the development of electroporation for delivery of DNA vaccines to humans. Mol Ther. 2004;9:S209-S09.
80. Groselj A, Kos B, Cemazar M, et al. Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online. 2015;14(Suppl 3):S2.
81. Calvet CY, Famin D, Andre FM, et al. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology. 2014;3:e28131.
82. Yang FQ, Yu YY, Wang GQ, et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat. 2012;19(8):581-593.
83. Kim CY, Kang ES, Kim SB, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med. 2008;40(6):669-676.